Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia

34Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is one of the hematological malignancies. With the applications of chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the cure rate of T-ALL has been significantly improved. However, patients with relapsed and refractory T-ALL still lack effective treatment options. Gene mutations play an important role in T-ALL. The NOTCH1 gene mutation is the important one among these genetic mutations. Since the mutation of NOTCH1 gene is considered as a driving oncogene in T-ALL, targeting the NOTCH1 signaling patheway may be an effective option to overcome relapsed and refractory T-ALL. This review mainly summarizes the recent research advances of targeting on NOTCH1 signaling pathway in T-ALL.

Cite

CITATION STYLE

APA

Zheng, R., Li, M., Wang, S., & Liu, Y. (2020, December 1). Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia. Experimental Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s40164-020-00187-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free